News and Announcements
CVC Add+Venture Fund on Track for a First Close of $10m in August
- Published August 03, 2017 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Capital raising for the CVC Add+Venture Fund is progressing well and based on applications already received we are on track for a first close of $10m this month (August).
We continue to assess great quality deal flow including a medical compliance and safety technology company with existing revenues, a platform for rapid web and app development, multiple cybersecurity opportunities, as well as a disruptive online B2C marketplace. The Add+Venture team is looking forward to closing the capital raise and turning our deal flow into investments in the Fund.
ABOUT CVC ADD+VENTURE FUND
The CVC Add+Venture Fund is a venture capital fund launched by CVC Limited, an ASX listed investment management company in operation since 1985, with net assets of over A$200 million. The Fund provides investors with tax effective access to the potentially outsized returns available from investing in early and expansion stage companies, utilising the experienced CVC Investment Team who have delivered returns in excess of 25% p.a. from CVC’s earlier stage portfolio over the past 5 years.
Company Updates
The Biofilm Breakthrough: How An Australian BioTech Firm Is Tapping Indonesia’s $45,000-a-Kitchen Bottleneck
Australian sustainability and deep-tech firm Altair International Pty Ltd is commercialising plant-based clinical hygiene technology, targeting a prime operational bottleneck in Indonesia’s massive national free meals program. Every few years, an Australian deep-tech company emerges combining proprietary science with a transformational anchor contract, the kind of business that quietly creates an entirely new market category […]
THE TAX CHANGED. NOW THE PRODUCT IS CHANGING TO MATCH.
Changes to the 50% capital gains tax discount are shifting Australian private capital away from growth and into high-yielding wrappers. Fund managers are actively redesigning products across private credit and property to capture the incoming capital rotation
The Algorithm Re-Dosing Cancer Treatment: Inside the University of Melbourne Spin-Out Rewriting a 60-Year-Old Formula
Oncology specialists are still calculating toxic chemotherapy doses using a formula from the era of the Ford Model T, leading to a system where seven out of eight patients are routinely overdosed. University of Melbourne spin-out PredicTx is dismantling this legacy approach, utilizing advanced AI to analyze existing patient CT scans, deliver precision medicine to the bedside, and return a massive 100x financial rerate to hospital networks.
Backed By Leading Investment Groups and Family Offices
